Abeona Therapeutics (NASDAQ:ABEO) Lowered to “Sell” Rating by StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Wednesday, February 19th.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock opened at $5.78 on Friday. The firm has a 50-day moving average price of $5.65 and a 200-day moving average price of $5.83. The firm has a market capitalization of $251.26 million, a PE ratio of -2.15 and a beta of 1.43. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. Adage Capital Partners GP L.L.C. lifted its holdings in Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after buying an additional 652,366 shares in the last quarter. Western Standard LLC lifted its holdings in Abeona Therapeutics by 22.8% during the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after buying an additional 386,321 shares in the last quarter. abrdn plc lifted its holdings in Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares in the last quarter. Jane Street Group LLC lifted its holdings in Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock valued at $732,000 after buying an additional 118,262 shares in the last quarter. Finally, 683 Capital Management LLC lifted its holdings in Abeona Therapeutics by 17.3% during the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after buying an additional 116,845 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.